Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology

Diagnostic Cytopathology

Volumn 40, Issue 8, 2012, Pages 667-672

  Knoepp, Stewart M ^a   Kunju, Lakshmi P ^a   Roh, Michael H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cytology; fine needle aspiration; PAX2; PAX8; renal cell carcinoma

Indexed keywords

TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8;

ARTICLE; ASPIRATION BIOPSY; CANCER CELL; CANCER CYTODIAGNOSIS; CELL NUCLEUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STAINING; TISSUE MICROARRAY; TISSUE SECTION;

BIOPSY, FINE-NEEDLE; CARCINOMA, RENAL CELL; CYTODIAGNOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; STAINING AND LABELING; TISSUE ARRAY ANALYSIS;

EID: 84864250754     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21590     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Murphy W, Grignon DJ, Perlman EJ,. Tumors of the kidney, bladder, and related urinary structures. In:, Steven G, Silverberg M, editors. Washington, DC: American Registry of Pathology; 2004. 394 p.
3. Ohnishi H, Abe M, Hamada H, et al. Metastatic renal cell carcinoma presenting as multiple pleural tumours. Respirology 2005; 10: 128-131.
4. Singla R, Bhattacharya D, Chhabra SK, Menon MP,. Pleural effusion in renal cell carcinomaâA rare presenting feature. Indian J Chest Dis Allied Sci 1987; 29: 29-35.
5. Ellis CL, Burroughs F, Michael CW, Li QK,. Cytology of metastatic renal medullary carcinoma in pleural effusion: A study of two cases. Diagn Cytopathol 2009; 37: 843-848.
6. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA,. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
7. Truong LD, Todd TD, Dhurandhar B, Ramzy I,. Fine-needle aspiration of renal masses in adults: Analysis of results and diagnostic problems in 108 cases. Diagn Cytopathol 1999; 20: 339-349.
8. Kunju LP, Wojno K, Wolf JS, Jr, Cheng L, Shah RB,. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: Expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 2008; 39: 96-101.
9. Leroy X, Farine MO, Buob D, Wacrenier A, Copin MC,. Diagnostic value of cytokeratin 7. CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma. Histopathology 2007; 51: 874-876.
10. Roh MH, Dal Cin P, Silverman SG, Cibas ES,. The application of cytogenetics and fluorescence in situ hybridization to fine-needle aspiration in the diagnosis and subclassification of renal neoplasms. Cancer Cytopathol 2010; 118: 137-145.
11. Wu A, Kunju LP, Cheng L, Shah RB,. Renal cell carcinoma in children and young adults: Analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation- associated and unusual clear cell subtypes. Histopathology 2008; 53: 533-544.
12. Dressler GR,. The specification and maintenance of renal cell types by epigenetic factors. Organogenesis 2009; 5: 73-82.
13. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007; 104: 331-337.
14. Roh MH, Kindelberger D, Crum CP,. Serous tubal intraepithelial carcinoma and the dominant ovarian mass clues to serous tumor origin? Am J Surg Pathol 2009; 33: 376-383.
15. Tong GX, Chiriboga L, Hamele-Bena D, Borczuk AC,. Expression of PAX2 in papillary serous carcinoma of the ovary: Immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol 2007; 20: 856-863.
16. Tung CS, Mok SC, Tsang YT, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009; 22: 1243-1250.
17. Chivukula M, Dabbs DJ, O'Connor S, Bhargava R,. PAX 2: A novel Mullerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol 2009; 28: 570-578.
18. Gokden N, Gokden M, Phan DC, McKenney JK,. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: An immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008; 32: 1462-1467.
19. Gokden N, Kemp SA, Gokden M,. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology. Diagn Cytopathol 2008; 36: 473-477.
20. Tong GX, Melamed J, Mansukhani M, et al. PAX2: A reliable marker for nephrogenic adenoma. Mod Pathol 2006; 19: 356-363.
21. Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63(-) immunostaining pattern in renal collecting duct carcinoma (CDC): A useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol 2010; 34: 965-969.
22. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010; 34: 627-635.
23. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: An immunohistochemical study. Mod Pathol 2009; 22: 1218-1227.
24. McKnight R, Cohen C, Siddiqui MT,. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: An immunohistochemical study of Metastatic ovarian serous carcinoma. Cancer Cytopathol 2010; 118: 298-302.
25. Tong GX, Devaraj K, Hamele-Bena D, et al. PAX8: A marker for carcinoma of Mullerian origin in serous effusions. Diagn Cytopathol 2010 [e-pub ahead of print].
26. Wiseman W, Michael CW, Roh MH,. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol 2010 [e-pub ahead of print].
27. Wasco MJ, Pu RT,. Comparison of PAX-2. RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration. Diagn Cytopathol 2008; 36: 568-573.
28. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis of primary renal tumors: Immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol 2009; 131: 393-404.
29. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2010; 18: 323-332.
30. Pan CC, Chen PC, Ho DM,. The diagnostic utility of MOC31. BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: An immunohistochemical analysis of 328 cases Histopathology 2004; 45: 452-459.
31. Wasco MJ, Pu RT,. Utility of antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma. Appl Immunohistochem Mol Morphol 2008; 16: 349-356.
32. Bakshi N, Kunju LP, Giordano T, Shah RB,. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: Diagnostic Implications. Appl Immunohistochem Mol Morphol 2007; 15: 310-315.